Strikingly, the survival benefit observed with RT + Conc.IT + aCD25 was lost by co-targeting CD8+ T cells in long-term preclinical trials of PDG-Ink4a glioblastoma-bearing mice (Fig. 6f, Extended Data Figs. 7 and 8k and Supplementary Table 1). The gene discussed is CDKN2A; the disease is glioblastoma.